Enliven Therapeutics, Inc. (ELVN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$59.32-0.55%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ELVN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -21.4% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ELVN — earnings miss
Dated 2026-08-05
and Item 9.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Why it matters: Watching cash burn is key. It helps us understand financial health and efficiency.
Worry ifOperating costs rise a lot above $29 million in Q3 2026.
Less concerning ifOperating costs stay the same or drop from $29 million in Q2 2026.
Why it matters: The debt issuance could affect how much cash the company has for operations and growth.
Watch forCash flow from operations gets much better after the company issues debt.
Also watch forCash flow from operations goes down or stays the same after the debt issuance.
Why it matters: Earnings results will show how well the company is growing and its financial health.
Watch forEarnings show a big rise in revenue compared to the last quarter.
Also watch forEarnings report reveals a decline in revenue or continued losses.
Why it matters: Earnings reports show financial health and progress. Results can change how investors feel.
Watch forEarnings report shows a big rise in revenue or a drop in losses.
Also watch forEarnings report reveals larger losses or no revenue growth.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$180 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $525 loss on $10,000 · 5.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,684 loss on $10,000 · 36.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: How well the debt issuance goes will affect Enliven's money situation and growth plans.
Watch forThe debt issuance is fully subscribed. This shows strong interest from investors.
Also watch forThe debt issuance does not attract enough investor interest. This leads to a smaller offering.
Why it matters: The debt issuance is important for funding operations. It shows good money management.
Watch forManagement provides details on how the debt will be used to support growth.
Also watch forNo updates or negative commentary on the impact of the debt issuance.
Why it matters: Good cash management is important. It helps keep operations running until ELVN-001 is ready.
Watch forReported R&D expenses decrease from $20.7 million to $18 million or lower.
Also watch forR&D costs rise above $20.7 million. This shows poor cash management.
Why it matters: Watching cash burn helps us understand financial health and how well operations can continue.
Worry ifThe cash burn rate goes down or stays steady in the next quarters.
Less concerning ifThe cash burn rate goes up a lot. This shows financial stress.
Why it matters: Positive Phase 1 data could strengthen the case for ELVN-001 as a leading treatment for CML.
Supportive ifThe presentation shows a major molecular response (MMR) rate over 61% in Phase 1b.
Worry ifThe presentation shows lower MMR rates or safety issues in the data.
Why it matters: Advancing clinical candidates is key for future revenue. Investors want to see progress.
Supportive ifA clinical trial for a treatment shows successful results.
Worry ifNo news or problems reported in trials for two quarters.
Why it matters: Improving expenses can help reduce cash burn. This is important for financial health.
Supportive ifOperating expenses in Q2 show a decrease compared to Q1.
Worry ifOperating costs go up or stay the same compared to Q1.
Why it matters: Starting this trial is key for advancing ELVN-001 in treating CML. It shows progress in clinical development.
Supportive ifENABLE-2 trial officially starts in the second half of 2026 as planned.
Worry ifThe ENABLE-2 trial may start later than 2026. This is due to regulatory or operational problems.
Why it matters: New data can strengthen the case for ELVN-001 as a leading treatment for CML.
Supportive ifPositive Phase 1 data will be shown at a big conference or meeting.
Worry ifNo new Phase 1 data presented or data shows weaker efficacy than prior results.
Why it matters: FDA alignment is crucial for the trial's success and can impact the timeline for ELVN-001.
Supportive ifFDA confirms the trial design and dosing for ENABLE-2 without major changes.
Worry ifThe FDA wants major changes to the trial design or dosing plan.